Profile and outcome of children with inborn errors of metabolism in a tertiary pediatric intensive care unit in South India by Sivaraman, Rajakumar Padur et al.
Vol 6 | Issue 3 | March 2019 Indian J Child Health 104
Original Article
Profile and outcome of children with inborn errors of metabolism in a tertiary 
pediatric intensive care unit in South India
Rajakumar Padur Sivaraman1, Umamaheswari Balakrishnan2, Sathya Chidhambaram3, Shruthi Tarikare1, 
Shuba Sankaranarayanan4
From 1Associate Professor, 3PG Student, 4Professor, Department of Pediatrics, 2Associate Professor, Department of Neonatology, Sri Ramachandra 
Institute of Higher Education and Research, Chennai, Tamil Nadu, India
Correspondence to: Dr. Umamaheswari Balakrishnan, Department of Neonatology, Sri Ramachandra Institute of Higher Education 
and Research, Chennai - 600 116, Tamil Nadu, India. E-mail: drumarajakumar@gmail.com
Received -  24 February 2018 Initial Review - 02 March 2019 Accepted - 05 March 2019
Inborn errors of metabolism (IEM) are individually rare but collectively common accounting for about 20% deaths from genetic disorders and nearly more than one-third of inherited 
neurological condition [1]. IEM are heterogeneous group of the 
disorder occurring due to a defect in the synthesis of enzyme 
or cofactor, transport of chemicals involving intermediary 
metabolites of carbohydrate, protein, or lipid. IEM presents 
as intoxication, which occurs due to the accumulation of 
intermediary metabolites, or as energy failure due to the failure 
of energy production or utilization or as storage of complex 
molecule resulting in storage disorders. Most of the disorders are 
of autosomal recessive inheritance.
Presentation occurs in the neonatal period or subsequently in 
the pediatric age group. The possibility of IEM should always be 
considered in a child with an unexplained, recurrent, or refractory 
illness. In those presenting in the pediatric age group, it is either 
the first manifestation precipitated by exercise, infection, excess 
protein intake or after prolonged fasting or the recurrence of the 
same signs which occurred during the neonatal period [2]. IEM 
can present as acute metabolic emergencies resulting in significant 
morbidity, progressive neurological injury, or death. Optimal 
outcome for children with IEM depends on recognition of signs 
and symptoms of the metabolic disease, prompt evaluation, and 
referral to a center familiar with evaluation and management of 
these disorders [3]. Good intensive care supportive management 
and specific metabolic crisis treatment by tertiary pediatric 
intensive care unit (PICU) play a crucial role in optimizing the 
outcomes.
Metabolic disorders should be recognized as one of the 
important etiologies in any child with the unexplained crisis with 
the background of consanguinity in pediatric ICU, especially 
with decreasing trends of infective etiology. The increasing 
availability of diagnostic biochemical testing in India enables 
definitive diagnosis of these rare inherited genetic condition [4]. 
The utility of the biochemical testing in the PICU setting has 
not been well studied. Furthermore, the data on these metabolic 
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disorders presenting as a medical emergency or as the metabolic 
crisis is sparse in India. Hence, we undertook this retrospective 
study with the aim to study the clinical profile, and outcome of 
children with IEM admitted in a tertiary PICU with an acute 
metabolic emergency.
METHODS
This retrospective descriptive study was conducted in a tertiary 
care center in South India between June 2016 and December 
2018. Our PICU is an accredited level III referral unit with an 
average annual admission of 1000 children. The metabolic clinic 
was started in our hospital in November 2014 and follow-up of 
metabolic patients take place in the metabolic clinic.
Children between 1 month and 18 years admitted in PICU 
with metabolic emergency and diagnosed to have IEM were 
included in the study. We included children diagnosed for the first 
time as IEM during the PICU stay and those who were diagnosed 
earlier either during newborn period or in the metabolic clinic. 
Children without a definitive diagnosis at the time of discharge or 
death were excluded from the study. Diagnosis of IEM was based 
on biochemical and/or molecular analysis. Biochemical testing 
done to confirm IEM include tandem mass spectrometry (TMS) 
for detecting abnormality in acylcarnitine profile and amino acid 
profile, and urinary gas chromatography-mass spectrometry 
(GC-MS) for detecting abnormality inorganic acids and plasma 
high-performance liquid chromatography (HPLC) for detecting 
abnormality in amino acid levels or other specific tests such as 
plasma very long chain fatty acid, cerebrospinal fluid, urine and 
plasma α-amino adipic semialdehyde (AASA), and pipecolic 
acid. Molecular analysis was done by utilizing next-generation 
sequencing and further validated by Sanger Squencing.
Data were collected retrospectively from the PICU register, case 
sheet from the medical record department and metabolic register. 
Clinical parameters collected include the age of presentation 
as a crisis, newly diagnosed or known entity, and age of initial 
diagnosis, sex, consanguinity, clinical signs and symptoms during 
the presentation, diagnosis, treatment, the outcome in terms of 
death, or discharge. Management details done including the 
specific measures for substrate reduction, supplementation of 
cofactors, removal of toxic metabolites, and supportive measures 
were collected. Details on biochemical tests done and the molecular 
analysis carried on these patients were studied. We included 
molecular testing done either immediately after the diagnosis or 
later from stored DNA. IEM were categorized as protein, lipid or 
carbohydrate metabolic disorder, vitamin responsive disorder, and 
peroxisomal or lysosomal storage disorder. Institutional Ethics 
Committee approval was obtained.
Categorical data were expressed as number and percentage 
and numerical data as median and interquartile range (IQR).
RESULTS
There were a total of 2815 children admitted in PICU in our hospital 
during the study period; out of which, 19 patients presented as 
a metabolic crisis or as a medical emergency and 15 children 
(0.53%) had IEM. Almost half of them (7/15) had been diagnosed 
in the neonatal period, five during evaluation for developmental 
delay before PICU admission, and three were diagnosed for the 
first time in PICU. Median (IQR) age of presentation in PICU 
was 15 months (10–30 months). Ten patients had more than one 
admission. Forty percent (6/15) were male. The majority (12/15) 
was born out of consanguineous marriage.
Spectrum of IEM presenting in PICU were as follows: 
Protein metabolic disorder-maple syrup urine disease 
(MSUD), propionic acidemia (PA), methylmalonic acidemia 
(MMA), citrullinemia type I and arginosuccinic aciduria 
(ASA);Fat metabolic disorder- HMG Co-A lyase deficiency, 
Succinyl CoA 3 oxoacid CoA transferase (SCOT) deficiency 
(ketolytic defect); Vitamin responsive disorders – Pyridoxine-
dependent seizures (PDS), multiple carboxylase deficiency 
(MCD); Peroxisomal disorder- Zellwegar biogenesis defect 
and Lysosomal storage disorder- glycogen storage disorder 
(GSD) type III. The number of children in each category has 
been depicted in Fig. 1. The conditions diagnosed for the first 
time in PICU were MMA, SCOT deficiency, and Zellweger 
biogenesis defect.
Details of the patients in terms of clinical presentation, 
medical management, and supportive care are depicted in Table 1. 
An emergency medical management plan was executed including 
initiation of high dextrose with GIR of 8–10 mg/kg/min with 
or without intralipid infusion of 1–2 g/kg/day in all diagnosed 
protein metabolic disorder patients. Further protein free formula 
was introduced followed by special formula and breastfeeding. 
Supportive care given during PICU stay was as follows: Six 
children required ventilator support and four managed with 
high flow nasal cannula support. Specific treatment includes the 
following: Four needed peritoneal dialysis (PD); nine needed 
special formulas, and seven of protein metabolic disorders 
needed specific vitamin cofactors as additional therapy. PDS 
and MCD were treated with pyridoxine and high dose biotin 
(80–100 mg/day), respectively.
Figure 1: Spectrum of inborn error of metabolism presenting in the 
pediatric intensive care unit. MSUD: Maple syrup urine disorder, 
PA: Propionic acidemia, MMA: Methylmalonic acidemia, Cit: 
Citrullinemia Type I, ASA: Argino succinic aciduria, HMG CoA: 
HMG Co A lyase deficiency, SCOT: Succinyl CoA 3 oxoacid CoA 
transferase deficiency, PDS: Pyridoxine dependent seizures, MCD: 
Multiple carboxylase deficiency, ZBD: Zellweger biogenesis disorder, 
GSD: Glycogen storage disorder type III
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Five children died either during first or subsequent crisis 
admission despite adequate medical management with a mortality 
of 33% during the ICU stay. Among six patients who needed 
mechanical ventilation, five died. Ten children were discharged 
and advised for regular follow-up in the metabolic clinic. A future 
emergency crisis management plan was modified taking into 
account the current status and handed over to the parents before 
discharge.
The results and the findings of biochemical testing done during 
PICU stay or earlier, aiding in the diagnosis of the individual 
condition, have been described in Table 2. Genetic counseling 
was done for all the parents. Molecular confirmation was done 
in 12 patients and is depicted in Table 3. Subsequent prenatal 
diagnosis was done for six mothers.
DISCUSSION
We present the cases of IEM presented in our PICU either as a 
metabolic emergency or as a crisis during a 2½ years period. IEM 
could potentially be underdiagnosed and high index of suspicion, 
and team effort is essential to diagnose IEM. Considering IEM in 
parallel with other common conditions is essential in the PICU 
Table 1: Clinical presentation, management, and outcome of patients with IEM
Case 
No.
Diagnosis Age#  
(month)
Age*  
(month)
Clinical 
presentation
Investigation  
(baseline)
Medical 
management
Intervention Outcome
1 MSUD 10 18 Generalized tonic 
clonic seizures 
Hypoglycemia lactic 
acidosis elevated 
lactates
Thiamine, 
levitracetam, 
phenytoin
Invasive 
ventilator 
support
Died
2 MSUD 8 10 Fever respiratory 
distress
Lactic acidosis Thiamine HFNC support Discharged
3 MSUD Neonatal 
period
10 Seizures failure to 
thrive
Hypokalemia 
lactic acidosis 
hyperammonemia
Thiamine, 
carnitine, 
clonazepam
Invasive 
ventilator 
support
Died
4 Propionic acidemia 5 11 Cough fever, 
lethargy 
dehydration
Hyperammonemia 
hypoglycemia 
metabolic acidosis 
ketosis
L carnitine 
Low protein 
diet
Ventilated, PD Died
5 Propionic acidemia Neonatal 
period
24 Lethargy, 
extrapyramidal 
movement
Hyperammonemia 
hypoglycemia 
metabolic acidosis 
ketosis
L carnitine 
low protein 
diet
HFNC, PD Discharged 
6 Methylmalonic 
acidemia
8 8 Seizures vomiting, 
tachypnea refusal 
to feed
High anion gap 
metabolic acidosis 
hyperammonemia
Vitamin B12 
L Carnitine
HFNC support Discharged 
7 Methyl melonic 
acidemia
24 36 Vomiting, refusal 
to feed
Hyperammonemia 
metabolic acidosis 
Vitamin B12 
L Carnitine
HFNC support Discharged 
8 Citrullinemia Neonatal 
period
13 One episode of 
seizure loss of 
consciousness
Hyperammonemia Protein 
restricted diet
Invasive 
ventilatory 
support, PD
Died
9 Arginosuccinicaciduria Neonatal 
period
18 Seizures, fever Hyperammonemia Protein 
restricted diet
Supportive care Discharged
10 SCOT deficiency 96 96 One episode 
of GTCS, 
encephalopathy, 
Flu-like symptoms 
Ketosis, high anion gap 
metabolic acidosis
High dextrose Ventilatory 
support
Died
11 HMG CoA lyase 
deficiency
Neonatal 
period
15 Reduced activity 
reduced oral intake
Hypoglycemia ketone 
negative
High dextrose Supportive care Discharged
12 Multiple carboxylase 
deficiencies
Neonatal 
period
30 One episode of 
GTCS
Hyperammonemia, 
metabolic acidosis
High dose 
Biotin
PD, ventilated Discharged 
13 Pyridoxine-dependent 
seizures
Neonatal 
period
3 Seizures, reduced 
activity
Baseline investigations 
normal
Pyridoxine, 
folinic acid
Supportive care Discharged
14 Zellweger spectrum 
disorder
8 8 Seizures- infantile 
spasms, reduced 
activity
Baseline investigations 
normal
Fat soluble 
vitamin 
supplements
Supportive 
care fat soluble 
vitamins, 
steroids
Discharged
15 GSD type III 54 60 Lethargy poor 
feeding
Hypoglycemia elevated 
ketones
Concentrated 
dextrose
Supportive care 
corn starch diet
Discharged 
Age #at diagnosis of IEM, *age at the time of last PICU admission, MSUD Maple syrup urine disease, GSD: Glycogen storage disorder, PD: Peritoneal dialysis, MSUD: Maple syrup 
urine disease, SCOT: Succinyl CoA 3 oxoacid CoA transferase, IEM: Inborn errors of metabolism, PICU: Pediatric intensive care unit, HFNC: High flow nasal cannula
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setting. Availability of advanced biochemical testing helped in the 
definitive diagnosis.
The most common IEM in our study was protein metabolic 
disorder accounting for 60% of the total IEM. Protein metabolic 
disorder including amino acid disorders, organic acidemia, and 
Urea cycle disorders (UCD) is known to present as metabolic 
crisis and that could be the possible reason for this being the most 
common disorder in PICU. A study done in Hyderabad where 
newborns were screened for IEM also found amino acid disorders 
to be as common as 1 in 3600 newborns [5]. It is possible that 
the same has been reflected in the PICU setting as well. We 
had three children with newly diagnosed conditions during the 
PICU admission. This is, in contrast, to the study by Kamate et 
al., where all 11 cases presented in PICU were newly diagnosed 
[6]. In our study, almost half have been diagnosed in the neonatal 
period itself, which is most likely to indicate a more severe 
spectrum of IEM. This could be due to the facility in our center 
to diagnose in the neonatal period itself with regular follow-up of 
these children in the metabolic clinic. Any child presenting with 
unexplained encephalopathy should have basic investigations 
including ammonia [7]. This simple test helps in picking up 
protein metabolic disorders including UCD and organic acidemia. 
We had one such newly diagnosed MMA in our study, presenting 
with hyperammonemia at 8 months of age which made us do 
detailed biochemical testing confirming the diagnosis of MMA.
In developed countries, newborn screening is being done 
widely for varying metabolic disorders. The conditions screened 
are 6, 29, and 23 conditions, in the UK, USA, and Australia, 
respectively [8]. Among the patients who presented for the first 
time, MMA could have been potentially picked up by NBS. 
Even in countries where screening is a part, van Karnebeek 
and Stockler, in a systematic review identified 81 treatable 
disorders as an etiology for intellectual disability [8]. In our 
study, we identified IEM in five children during the evaluation 
of developmental delay. There are few disorders which cannot 
be picked up by newborn screening. This includes disorders 
such as PDS, Zellweger biogenesis disorder (ZBD), and GSD. 
As expected, the yield of baseline investigation as well as TMS, 
GCMS, and HPLC was low in detecting PDS and ZBD even in 
our study. Although PDS typically presents in the neonatal period 
(within a month), it can present atypically up to 3 years of age [9]. 
Any seizures which are refractory presenting in this age group 
warrant a trial of pyridoxine. In our study, the PDS was diagnosed 
in the neonatal period itself.
Treatment modalities of any IEM include a reduction in 
substrate availability, supplementation with enzyme or cofactors, 
providing deficient metabolite and removal of a toxic metabolite 
[3,10-12]. The same strategy was utilized in treating our patients 
admitted in PICU. Although hemodialysis is more efficient in 
clearing the toxic metabolite, the ease and cost-effectiveness 
Table 2: Biochemical analysis which aided in definite diagnosis
Case 
No.
Diagnosis TMS GCMS HPLC Other specialized tests
1,2,3 MSUD ↑ Leucine/
Isoleucine
2 OH, valeric acid,
2 OH 3 Methyl valeric acid
N-Ac- leucine
↑ branched chain amino 
acids
-
4,5 Propionic acidemia ↑ C3 and C3/C2 OH propionic acid, propionyl 
glycine, tiglylglycine
↑ glycine -
6,7 Methylmalonic 
Acidemia
↑ C3 and C3/C2 Methylmalonic acid Normal Quantitative elevation of 
MMA
8 Citrullinemia type I ↑ citrulline Normal ↑ Citrulline and low 
arginine
Low ASA
9 Arginosuccinic aciduria ↑ citrulline Normal ↑ Citrulline  
and ↑ Glutamic acid ↓ 
Arginine 
Elevated ASA
10 Succinyl CoA 
3 oxoacid CoA 
transferase (SCOT) 
deficiency
↑ C4OH and 
C4OH/C2
Elevated lactic acid, 
2-OHbutric acid, 3-OHbutric 
acid
Non-specific elevation 
of multiple amino acids
-
11 HMG CoA lyase 
deficiency
↑ C5OH 3 Oh isovaleric acid, three 
methyl glutaconic acid, three 
OH Methyl glutaric acid
Normal -
12 Multiple carboxylase 
deficiencies 
↑ C5OH 3 methyl crotonyl glycine, 
methyl citrate
Normal -
13 Pyridoxine-dependent 
seizures
Normal Normal Normal Elevated AASA and 
pipecolic acid in plasma 
and urine
14 ZBD Normal Normal Normal Elevated VLCFA and 
low plasmologen
TMS: Tandem mass spectrometry, GCMS: Gas chromatography‑mass spectrometry, HPLC: High‑performance liquid chromatography, MSUD: Maple syrup urine disease; 
MMA: Methylmalonic acid, ASA: Arginosuccinic aciduria, AASA: α‑aminoadipic semialdehyde, VLCFA: Very long chain fatty acid, ZBD: Zellweger biogenesis disorder
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Table 3: Molecular analysis for the study population
Cases Diagnosis Gene Variant Zygosity Variant
Case 1 MSUD BCKDHB Exon 1
c. 3G>A;
Exon 5
c. 484A>G
Compound  
heterozygous
Pathogenic
Case 2 MSUD BCKDHA Exon 9
c. 1312T >C
Homozygous Pathogenic
Case 3 MSUD BCKDHB Exon 4
c. 410C >T
Homozygous Pathogenic
Case 4 Propionic acidemia PCCA Exon 13
c. 1195C >T
Homozygous Pathogenic
Case 5 Propionic acidemia PCCA Exon 12
c. 937C >T
Homozygous Pathogenic
Case 6 Methylmalonic acidemia MUT(-) Exon 3
c. 643G >T
Homozygous Pathogenic
Case 8 Citrullinemia Type I ASS1 Exon 15
c. 1168G >A
Homozygous Pathogenic
Case 9 Arginosuccinicaciduria ASL Intron 11
c. 918+5G >A
Homozygous Pathogenic
Case 12 HMG CoA lyase deficiency HMGCL Exon 7
c. 602C >A
Homozygous Pathogenic
Case 13 Pyridoxine-dependent seizures ALDH7A1 Exon 9
c. 841C >T
Homozygous Pathogenic
Case 14 ZBD- I B PEX1 Exon 5
c. 1108del A
Homozygous Pathogenic
Case 15 GSD type III AGL Exon 31:
c. 4256dup
Homozygous Pathogenic
MSUD: Maple syrup urine disease, GSD: Glycogen storage disorder, ZBD: Zellweger biogenesis disorder
make PD ASA- as a useful modality. Among the four patients 
who underwent PD, two survived. Administration of vitamins 
like pyridoxine could be the only treatment for PDS, whereas 
giving biotin and other factors would generally form an additional 
modality for conditions like PA. Carnitine either as parenteral 
or oral therapy also help in the removal of toxic metabolite 
especially in organic acidemias and we promptly initiated that in 
needed children. Special formula was used to provide deficient 
metabolite and to reduce the substrate availability. After the acute 
crisis, breastfeeding was encouraged along with special formula 
in protein metabolic disorders as an amino acid load of breastmilk 
is low [13]. Low protein diet was initiated in older children with 
protein metabolic conditions at the time of discharge. As a patient 
with GSD is more prone for hypoglycemia, especially after 
moderate fasting, uncooked corn starch which is a form of complex 
carbohydrate was started to prevent further hypoglycemia.
In our study, biochemical testing which helped in arriving at 
specific diagnosis was elaborated. It is important to request for 
GCMS and HPLC along with TMS, as TMS alone would act only 
as a screening tool and not a diagnostic tool. All the information 
got from the test results have to be taken holistically to arrive 
at a specific diagnosis. TMS, GCMS, and HPLC are the most 
common diagnostic modality to aid in definitive diagnosis [1,8]. 
Very long fatty acid assay, plasma and urine AASA, and pipecolic 
acid are some of the specialized metabolic testing utilized in our 
study cohort.
Molecular testing was done in 80% of the study cohort. We 
could confirm using molecular analysis in a higher proportion as 
we included testing done from stored DNA. It is a good practice 
to store DNA even when the testing cannot be done at an acute 
state during PICU admission. As all the conditions in the present 
study are inherited in an autosomal recessive manner, we got 
92% (11/12) of a pathogenic variant in homozygous status and 
only 8% (1/12) as compound heterozygous. In India due to the 
high prevalence of consanguineous marriage and endogamous 
population [14], there is a high chance of these condition occurring 
in the homozygous state rather than the compound heterozygous 
state. Notably, GSD type III was made only using the molecular 
method. In the present genomic era, next-generation sequencing 
is the most common test utilized to detect single gene disorder. 
This could be due to the genetic heterogeneity of many of the 
IEM where >1 gene is responsible for the same phenotype. Exome 
sequencing is an effective technology for diagnosing metabolic 
disorders [15]. We also got one intronic variant, which would 
have been missed if exome sequencing alone is done. Molecular 
analysis has not only helped the index child but also in prenatal 
diagnosis in 50% of the families.
Mortality occurred in five patients out of 15. Mortality is 
similar to that of the previous PICU study done in India [6]. One 
of the patients who died was diagnosed to have H3N2 influenza 
infection. He was an 8-year-old boy who was otherwise normal 
presenting with ketoacidosis and diagnosed to have SCOT 
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deficiency by biochemical testing. This reiterates the fact that 
metabolic disorders can be precipitated by infection. A previous 
case report describes another ketolytic defect, namely beta-
ketothiolase deficiency presenting as metabolic encephalopathy at 
11 months of age [16]. Whenever there is ketoacidosis, intensivists 
apart from diabetic ketoacidosis should suspectketolytic defect 
especially when there is no hyperglycemia or glycosuria. Need 
for mechanical ventilation is associated with high mortality in our 
study.
As this study describes only the short-term outcome, it is not 
taking into account the death that could potentially happen outside 
the study period or which could happen at a different hospital or 
home. This is one of the limitations of the study. Strengths of 
our study are a detailed description of biochemical testing aiding 
the definitive diagnosis and high proportion (80%) of a patient 
having molecular confirmation.
CONCLUSION
The most common cause for metabolic crisis in PICU is due 
to protein metabolic disorder. Aggressive intensive care and 
IEM directed therapy can be lifesaving, but still, the mortality 
is high. Need for mechanical ventilation is associated with poor 
prognosis. As IEM occurred uncommonly in PICU, a centralized 
database with inputs from all tertiary care centers would give a 
better insight about the individual conditions.
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